

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/079094 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) *A61P 1/04* (2006.01)
A61K 31/437 (2006.01) *A61P 1/06* (2006.01)
A61P 1/00 (2006.01)

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/080850

(22) International Filing Date:

04 November 2022 (04.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/128918

05 November 2021 (05.11.2021) CN

(71) Applicant: CINCLUS PHARMA HOLDING AB

(PUBL) [SE/SE]; Kungsbron 1, Level 3, Elevator G, 111 22 Stockholm (SE).

(72) Inventors: JARRING, Kjell; Astrid Lindgrens väg 2A, 224 66 Lund (SE). LARSSON, Thomas; Hölländarehusvägen 74, 237 33 Bjärred (SE). LIN, Xingbang; c/o Lonza Guangzhou Pharmaceutical Ltd., 68, Huangge Dadaobei, Nansha District, Guangzhou, Guangdong 511455 (CN). WANG, Dan; c/o Lonza Guangzhou Pharmaceutical Ltd., 68, Huangge Dadaobei, Nansha District, Guangzhou, Guangdong 511455 (CN). HILLGREN, Mikael; Bygmästargatan 11B, 754 35 Uppsala (SE).

(74) Agent: NOVITAS PATENT AB; P.O.Box 55557, 102 04 Stockholm (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

Published:

— with international search report (Art. 21(3))

WO 2023/079094 A1

(54) Title: POLYMORPHS OF THE HYDROCHLORIDE SALT OF LINAPRAZAN GLURATE

(57) Abstract: The present invention relates to polymorphs of the hydrochloride salt of 5-{2-[(8-{(2, 6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazan glurate), more specifically Form 1 and Form 2 of the MCI salt of linaprazan glurate. The invention also relates to a process for the preparation of such polymorphs, to pharmaceutical compositions comprising such polymorphs, and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory diseases or gastric acid related diseases, in particular erosive gastroesophageal reflux disease (eGERD).